Compare Quest Diagnostics Inc (DGX) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Toronto-Dominion Bank — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Toronto-Dominion Bank trades at $115.1 (market cap $185.79B). The key difference: Toronto-Dominion Bank is far larger — about 7.3× Quest Diagnostics Inc's market cap, and Toronto-Dominion Bank pays the higher dividend (2.84%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Toronto-Dominion Bank for 84 Days on average.
| DGX | TD | |
|---|---|---|
Market Cap | $25.48B | $185.79B |
Volume | 941,866 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $247.45 | $124.80 |
52-Week Low | $173.49 | $78.32 |
Typical Hold Time | 56 Days | 84 Days |
Enterprise Value | $31.23B | $559.06B |
Dividend Yield | 1.49% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
TD Bank trades at $114.04, up 0.15% with a P/E of 17.36 and strong profitability metrics including 24.88% net income margin. Recent earnings have consistently beaten expectations, with three consecutive quarterly beats. Technical indicators show bearish momentum despite oversold RSI readings. The company announced a $10 billion share buyback program and $108 billion Canadian infrastructure commitment, signaling confidence in future growth.
The outlook remains positive with analyst consensus favoring Buy ratings (52.94%) and strong fundamentals, though technical weakness and increasing debt-to-asset ratios present near-term challenges. Revenue growth trajectory from $61.3B to projected $65.1B supports long-term investment case, while volatile cash flows require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
